AbbVie acquires Penn spinoff Capstan for .1 billion to develop cell-based treatments for autoimmune diseases.
AbbVie, a leading pharmaceutical company, has announced its acquisition of Capstan Therapeutics, a biotechnology firm developed at the University of Pennsylvania, for an estimated .1 billion. This acquisition is indicative of AbbVie’s commitment to expanding its portfolio in the rapidly evolving field of autoimmune disease treatments. The deal is regarded as one of the most significant pharmaceutical agreements of the year, reinforcing the growing interest in innovative therapies that engineer immune cells within the body.
Capstan Therapeutics specializes in developing in vivo CAR-T (Chimeric Antigen Receptor T cell) therapy, aimed at making this cutting-edge treatment more accessible, affordable, and applicable to a broader spectrum of health conditions, particularly autoimmune diseases. Traditional CAR-T therapy involves extracting T cells from patients, enhancing them to target cancerous cells, and reinfusing them into the body. While this approach has yielded remarkable success in treating certain types of blood cancers, such as childhood leukemia, the high costs—often exceeding 5,000—and the intricate procedures have limited its accessibility to a handful of specialized health centers, which underscores the potential market opportunity that Capstan represents.
The founders of Capstan include prominent figures in the medical field, such as Carl June, a pioneer in CAR-T therapy, and Drew Weissman, a Nobel laureate recognized for his research in mRNA technology used in COVID-19 vaccines. Current efforts at Capstan focus on enabling the conversion of a patient’s own T cells into CAR-T cells within the body, thereby offering a streamlined treatment process that could be administered via a single outpatient injection, as opposed to the extensive hospital stay currently required.
The spike in autoimmune diseases—which affect approximately 8% of the U.S. population—highlights an urgent need for new therapeutic options. Disorders in this category occur when the immune system mistakenly attacks healthy cells, often leaving patients with limited or no effective treatments. AbbVie’s commitment to investing in Capstan aims to change this landscape, focusing on treatments that offer hopeful prospects for resetting the immune system.
As regulatory trials progress, Capstan will benefit from increased resources and support under AbbVie’s infrastructure, accelerating its path toward clinical approval and market introduction of its pioneering therapies. Initial human trials for Capstan’s innovative treatments began in June, and the results will be closely monitored as the biotech community remains vigilant regarding safety concerns associated with CAR-T therapies. The acquisition allows Capstan to advance its research and development significantly, marking a pivotal point in its mission to tackle some of the most challenging medical conditions.
The terms of the acquisition and a timeline for its completion have yet to be disclosed, but the deal underscores a broader trend of interest in in vivo therapies within the biotechnology sector, which is increasingly viewed as a frontier for next-generation therapies.
